M42’s New Platforms to Drive Innovation in Health Care

As part of the next stage of its growth journey, Abu Dhabi-based M42, a global health leader powered by artificial intelligence (AI) and technology, has announced the creation of a new operating structure to drive innovation in healthcare, focus the business on strategic priorities and accelerate local and international business growth.

The four platforms are; include Global Patient Care, Integrated Health Solutions, Digital Health solutions and AI Life Solutions.

With the creation of these new platforms, the new structure is designed to support M42’s strategic growth ambitions, including organic and inorganic growth, expansion into new markets, the formation of impactful partnerships to plug global healthcare gaps, and harnessing AI to disrupt traditional healthcare systems.

M42 at the group level will focus on strategy, strategic mergers and acquisitions, corporate finance, strategic human capital, legal, strategic communications, global procurement, and internal audit and risk.

The new operating model also includes the establishment of four platforms, which will operate with greater autonomy, responsibility, and accountability as they grow and fulfil the shared ambition of M42.

Global Patient Care

By integrating the UAE and international health assets, this platform has emerged as a leading global healthcare organisation, operating 480 clinics across 26 countries and serving 15 million patients annually.

The services offered through this platform include renal care, outpatient and chronic disease management, diagnostics, women & child Health, specialty surgery, and long-term care. Dimitris Moulavasilis, currently CEO of M42’s Diaverum and Acting Group COO of M42, has been appointed Chief CEO of this platform.

Integrated Health Solutions

Concentrating on national programs and population health, this platform aims to address global health disparities through precise, preventive and predictive care. It will include M42’s focus on genomics, national programs, biobank, data services, environmental sciences, and clinical research and trials. Dr Fahed Al Marzooqi will lead as Chief Executive Officer.

Digital Health Solutions

This platform will scale digital health innovations and AI-driven solutions to enhance patient outcomes, empower healthcare providers and ecosystems and improve healthcare access in the UAE and abroad. Kareem Shahin will serve as CEO of the platform.

AI Life Sciences

Focused on drug discovery and development, this pioneering platform will harness AI and partnerships across the life sciences value chain and focus on building M42’s capabilities in space. Dr Fahed will be the Acting CEO of the platform until a chief executive is appointed.

M42’s continued focus on cloud, technology, and engineering will underpin all platforms and enable their delivery for people, communities, and nations.

M42 in Bahrain

It may be recalled that M42 has expanded its footprint to Bahrain in partnership with the Kingdom’s sovereign wealth fund, Bahrain Mumtalakat Holding Company, and into the UAE’s northern emirates after entering into a strategic investment partnership with the UAE’s Ministry of Defence.

Zayed Military Hospital in Al Batayeh, Sharjah, managed and operated by M42 in collaboration with the Ministry of Defence, has now been renamed Sheikh Sultan bin Zayed Hospital.

In 2023, M42 acquired Diaverum, a leading global renal care service provider, from Bridgepoint Group. Founded in 1991, Diaverum is currently the world’s third-largest provider of dialysis services, operating across 24 countries, with 450 clinics and over 13,000 employees.